MedPath

Comparing two different techniques in providing pain relief for better positioning of patient while performing injection at the back of spine in patients undergoing hip fracture surgeries

Not yet recruiting
Conditions
Other Procedures,
Registration Number
CTRI/2020/09/027893
Lead Sponsor
SRM Medical College Hospital And Research Centre
Brief Summary

Patients who met the inclusion criteria will be randomly allocated into two groups, Group A and Group B with  30 in each group based on computer generated random envelope method. Group F patients will receive 30 ml of 0.5% Ropivacaine for FICB (Fascia iliaca compartment block)  and Group P patients will receive PENG block.

All patients will receive premedication with tablet alprazolam 0.5 mg per oral 2 hours before shifting to the operating theatre. Once the patient is shifted to premedication room, the patient’s vitals were monitored using pulse oximetry, NIBP and ECG. After taking proper aseptic precautions, under ultrasound guidance, Fascia Iliaca Compartment Block will be given using 30 ml of 0.5% ropivacaine on group F patients. Group P patients will receive PENG Block with 20 ml of 0.75% Ropivacaine. After 15 minutes of administration of the block in both the groups, the patients will be shifted to the operation theatre and spinal anaesthesia will be given  using 3 ml of 0.5% bupivacaine (heavy). Intra-operatively patient will be monitored for heart rate, blood pressure, oxygen saturation, input and output monitoring. All the patients will be postoperatively monitored in the  recovery room for 2 hours and then shifted to PACU . Post-operative pain will be assessed by visual analog scale (VAS). Supplementary analgesics i.e. Inj. Paracetamol 1000mg(IV) will be given if the patient had elicited a VAS score of 3 to 5 and Inj. Tramadol 100 mg (IV) will be given if the patient has a VAS score of more than 5. Total consumption of Paracetemol and Tramadol for 24 hours will be noted.

Patient positioning score during spinal anaesthesia was assessed depending on the patient’s sitting comfort during administration of spinal anaesthesia.

0 – not satisfactory,

1 – satisfactory,

2 – Good,

3 – Optimal.

**VISUAL ANALOG SCALE**:

The pain will be assessed by visual analog scale (VAS), measured at rest.

0 = no pain at all

1–2 = mild pain intensity

3–5 = moderate pain intensity

6–8 = severe pain intensity

9–10 = worst pain ever felt.

The duration of postoperative analgesia is defined as the time taken from the completion of FICB and PENG block to the first request for postoperative analgesia (VAS > 3).

If the patient has VAS of 3 to 5 then Inj. Paracetamol 1g IV will be given and for VAS>5, inj tramadol will be given. The total consumption of tramadol and paracetamol will be noted. The occurrence of any adverse effects like nausea, vomiting, itching and respiratory depression will be noted and treated accordingly

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

ASA 1 2 3 Patients admitted for elective and emergency hip fracture surgeries under spinal anaesthesia.

Exclusion Criteria

patient refusal, any contra indication for spinal anaesthesia, infection at the site of block, allergy to local anaesthetic drugs or other medications used in the study, coagulopathy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of quality of positioning for spinal anaesthesia for hip fracture surgeriesFrom starting until end of performing spinal anesthesia
Secondary Outcome Measures
NameTimeMethod
1)To evaluate the duration of post-operative analgesia2)Requirement of post-operative analgesics for 24 hrs.

Trial Locations

Locations (1)

SRM Medical College Hospital And Research Centre

🇮🇳

Kancheepuram, TAMIL NADU, India

SRM Medical College Hospital And Research Centre
🇮🇳Kancheepuram, TAMIL NADU, India
Dr Parameshwaran M
Principal investigator
9994613023
daredoparam@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.